Grigoropoulou Pinelopi, Tentolouris Anastasios, Eleftheriadou Ioanna, Tsilingiris Dimitrios, Vlachopoulos Charalambos, Sykara Maria, Tentolouris Nikolaos
1 Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
2 First Department of Cardiology, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.
Diab Vasc Dis Res. 2019 Jan;16(1):38-46. doi: 10.1177/1479164118805320. Epub 2018 Oct 17.
Cardiovascular disease is the leading cause of morbidity and mortality in subjects with type 2 diabetes mellitus. Increased aortic stiffness, assessed with the carotid-femoral pulse wave velocity, is an independent risk factor for cardiovascular disease. Statins reduce effectively cardiovascular disease and mortality in high-risk patients. The aim of this prospective non-randomized, observational study was to examine the impact of treatment with either 10 mg atorvastatin plus diet or diet alone on carotid-femoral pulse wave velocity in subjects with type 2 diabetes mellitus and dyslipidaemia. A total of 79 subjects with type 2 diabetes mellitus and dyslipidaemia were included; 46 subjects were treated with atorvastatin 10 mg daily plus diet and 33 were managed by diet alone for 12 months. Carotid-femoral pulse wave velocity and carotid-radial pulse wave velocity were measured using applanation tonometry. In the atorvastatin-treated group, carotid-femoral pulse wave velocity reduced significantly during the study and there was a trend for reduction in the carotid-radial pulse wave velocity. Total cholesterol, low-density lipoprotein cholesterol, triglycerides and C-reactive protein were reduced only in the atorvastatin-treated participants. No significant changes were found in body mass index, blood pressure, heart rate, diabetes control and high-density lipoprotein cholesterol in either study group. Treatment with low-dose atorvastatin for 12 months improves carotid-femoral pulse wave velocity in subjects with type 2 diabetes mellitus and dyslipidaemia.
心血管疾病是2型糖尿病患者发病和死亡的主要原因。通过颈股脉搏波速度评估的主动脉僵硬度增加是心血管疾病的独立危险因素。他汀类药物可有效降低高危患者的心血管疾病发生率和死亡率。这项前瞻性非随机观察性研究的目的是研究10毫克阿托伐他汀联合饮食治疗或单纯饮食治疗对2型糖尿病和血脂异常患者颈股脉搏波速度的影响。总共纳入了79例2型糖尿病和血脂异常患者；46例患者接受每日10毫克阿托伐他汀联合饮食治疗，33例患者仅接受饮食治疗12个月。使用压平式眼压计测量颈股脉搏波速度和颈桡脉搏波速度。在阿托伐他汀治疗组中，研究期间颈股脉搏波速度显著降低，颈桡脉搏波速度有降低趋势。仅在阿托伐他汀治疗的参与者中，总胆固醇、低密度脂蛋白胆固醇、甘油三酯和C反应蛋白降低。两个研究组的体重指数、血压、心率、糖尿病控制情况和高密度脂蛋白胆固醇均未发现显著变化。低剂量阿托伐他汀治疗12个月可改善2型糖尿病和血脂异常患者的颈股脉搏波速度。
